498 related articles for article (PubMed ID: 28800752)
1. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
3. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
[TBL] [Abstract][Full Text] [Related]
5. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
6. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.
Huang Y; Rachid Z; Jean-Claude BJ
Mol Cancer Res; 2011 Mar; 9(3):320-31. PubMed ID: 21263032
[TBL] [Abstract][Full Text] [Related]
7. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro.
Turriziani M; Caporaso P; Bonmassar L; Buccisano F; Amadori S; Venditti A; Cantonetti M; D'Atri S; Bonmassar E
Pharmacol Res; 2006 Apr; 53(4):317-23. PubMed ID: 16412662
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
9. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
10. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
12. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
14. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase.
Tentori L; Lacal PM; Benincasa E; Franco D; Faraoni I; Bonmassar E; Graziani G
J Pharmacol Exp Ther; 1998 May; 285(2):884-93. PubMed ID: 9580640
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
19. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.
Cai W; Maldonado NV; Cui W; Harutyunyan N; Ji L; Sposto R; Reynolds CP; Keshelava N
Br J Cancer; 2010 Oct; 103(9):1369-79. PubMed ID: 20924375
[TBL] [Abstract][Full Text] [Related]
20. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]